Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > BloomBurton initiated coverage with a BUY yesterday

<< Previous

Bullboard Posts

Next >>

Comment by Mbxwatcheron Jun 07, 2022 10:14am

156 Views

Post# 34736732

RE:BloomBurton initiated coverage with a BUY yesterday

....extremely conservative valuation.....no value whatsoever for Kinlytic, and no real confidence a deal will get done.
.... no growth factored in for VTM at all
.... very little growth in antigen business, 6% annually
.....seem to agree with QAPS growth but they need to see evidence from Management that they deals they are building toward will happen.

Not a dissappointing initial coverage letter, but they seem to take the position of "show me" on the growth curve.....

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”